ENGLEWOOD, Colo., Oct. 2, 2019 /PRNewswire/ -- Zynex, Inc.
(NASDAQ: ZYXI), an innovative medical technology company
specializing in manufacturing and selling non-invasive medical
devices for pain management, stroke rehabilitation, cardiac
monitoring and neurological diagnostics, today announced 95% year
over year order growth for the third quarter 2019.
Orders in the third quarter of 2019 grew 95% compared to the
third quarter of 2018 and 30% above the second quarter of 2019. In
the second quarter of 2019, orders grew 65% year-over-year.
Thomas Sandgaard, CEO of Zynex,
said: "The investment in our sales force expansion is clearly
beginning to bear fruit. Our prescription-strength NexWave device
is clearly a healthy alternative to prescribing opioids as the
first line of defense when treating pain. We continue to
aggressively add additional sales reps in territories throughout
the U.S. that we have not covered previously.
"We advocate for pain patients, and for physicians to prescribe
our NexWave technology as the first line of defense in treating
chronic and acute pain without side effects. We are dedicated to
promoting our technology in an effort to remove patient addiction
and other side effects from prescription opioids."
About Zynex
Zynex, founded in 1996, markets and sells its own design of
electrotherapy medical devices used for pain management and
rehabilitation; and the company's proprietary NeuroMove device
designed to help recovery of stroke and spinal cord injury
patients. Zynex is also developing a new blood volume monitor for
use in hospitals and surgery centers. For additional
information, please visit: Zynex.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" or
projections and as such are subject to numerous risks and
uncertainties. The company makes no express or implied
representation or warranty as to the completeness of this
information or, in the case of projections, as to their
attainability or the accuracy and completeness of the assumptions
from which they are derived. Actual results may vary significantly
from the results expressed or implied in such statements. Factors
that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the
need to obtain FDA clearance and CE marking of new products, the
acceptance of new products as well as existing products by doctors
and hospitals, larger competitors with greater financial resources,
the need to keep pace with technological changes, our dependence on
the reimbursement for our products from health insurance companies,
our dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales
strategy including a strong direct sales force and other risks
described in our filings with the Securities and Exchange
Commission including the "Risk Factors" section of our Annual
Report on Form 10-K for the year ended December 31,
2018 as well as Forms 10-Q, 8-K and 8-K/A, press releases and
the Company's website.
Contact:
Zynex, Inc.
(303) 703-4906
Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zynex-announces-95-order-growth-300929542.html
SOURCE Zynex, Inc.